arrow_back Back to App

Drug Price Transparency: Ads Must Show Costs

New legislation mandates that advertisements for prescription drugs and biological products include their pricing information. This aims to empower citizens to make informed choices about their medications and better manage personal finances before committing to a specific treatment.
Key points
Direct-to-consumer advertisements for prescription drugs and biological products will be required to clearly display their wholesale acquisition cost for a 30-day supply.
The goal is to increase price transparency, helping patients understand potential costs before receiving a prescription.
The law applies to drugs with a wholesale acquisition cost of $35 or more for a 30-day supply.
Manufacturers failing to comply may face civil penalties of up to $100,000 per violation.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_3789
Sponsor: Rep. Taylor, David J. [R-OH-2]
Process start date: 2025-06-05
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

DTC Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_3789.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-06-05.

What are the main provisions?

Key points include:

  • Direct-to-consumer advertisements for prescription drugs and biological products will be required to clearly display their wholesale acquisition cost for a 30-day supply.
  • The goal is to increase price transparency, helping patients understand potential costs before receiving a prescription.
  • The law applies to drugs with a wholesale acquisition cost of $35 or more for a 30-day supply.
  • Manufacturers failing to comply may face civil penalties of up to $100,000 per violation.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Taylor, David J. [R-OH-2].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health